company background image
VBIV

VBI VaccinesNasdaqCM:VBIV Stock Report

Market Cap

US$715.3m

7D

-6.7%

1Y

-4.1%

Updated

27 Nov, 2021

Data

Company Financials +
VBIV fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

VBIV Stock Overview

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology.

VBI Vaccines Competitors

Dynavax Technologies

NasdaqCM:DVAX

US$2.0b

Merck

NYSE:MRK

US$200.0b

GlaxoSmithKline

LSE:GSK

UK£75.7b

Price History & Performance

Summary of all time highs, changes and price drops for VBI Vaccines
Historical stock prices
Current Share PriceUS$2.78
52 Week HighUS$4.83
52 Week LowUS$2.45
Beta1.93
1 Month Change-7.33%
3 Month Change-22.35%
1 Year Change-4.14%
3 Year Change73.75%
5 Year Change-10.32%
Change since IPO-85.11%

Recent News & Updates

Oct 31

VBI Vaccines: Hepatitis Vaccine Approval Can Be A Catalyst For >$1bn Valuation

VBI Vaccines will find out on November 30th whether its Hepatitis B vaccine - already approved in Israel - will be approved by the FDA in the US. Approval in the US - and Europe, where a marketing authorization is also being sought - could be a potential game-changer for the company, although this is a tricky market. VBI has several COVID vaccines in development, designed to complement existing, approved ones, which are early stage but focused on e.g. durability of response. VBI's use of Virus Like Particles and lipid layer of protection is novel and promising, and can also be applied to other infectious diseases and cancers. An approval next month could push the company's valuation past $1bn, in my view, representing 25% upside. And longer term, the outlook looks promising - although possibly only to die-hard biotech investors.

Oct 06
Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?

Is VBI Vaccines (NASDAQ:VBIV) Weighed On By Its Debt Load?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

Jul 15

VBI Vaccines: Turning My Focus To VBI-1901

My coverage of VBI Vaccines has been overly focused on the company’s infectious disease programs and I have discounted the company’s glioblastoma candidate, VBI-1901. The company presented impressive Phase IIa that showed improvements in response rates and overall survival compared to historical data. The FDA granted VBI-1901 a Fast Track Designation which validates VBI-1901's clinical prowess and the urgent unmet medical need for new glioblastoma therapies. I believe my fixation on the company's infectious disease programs has distorted my VBIV time horizon. I provide an update on my revamped VBIV strategy.

Shareholder Returns

VBIVUS BiotechsUS Market
7D-6.7%0.4%-2.7%
1Y-4.1%5.3%21.3%

Return vs Industry: VBIV underperformed the US Biotechs industry which returned 5.3% over the past year.

Return vs Market: VBIV underperformed the US Market which returned 21.3% over the past year.

Price Volatility

Is VBIV's price volatile compared to industry and market?
VBIV volatility
VBIV Average Weekly Movement6.6%
Biotechs Industry Average Movement8.6%
Market Average Movement6.0%
10% most volatile stocks in US Market15.0%
10% least volatile stocks in US Market2.3%

Stable Share Price: VBIV is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.

Volatility Over Time: VBIV's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
n/a130Jeff Baxterhttps://www.vbivaccines.com

VBI Vaccines Inc., a biopharmaceutical company, develops and sells vaccines for the treatment of infectious diseases and immuno-oncology. The company offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. It also engages in the development of VBI-2601 (BRII-179), an immunotherapeutic candidate for the treatment of chronic HBV infection.

VBI Vaccines Fundamentals Summary

How do VBI Vaccines's earnings and revenue compare to its market cap?
VBIV fundamental statistics
Market CapUS$715.31m
Earnings (TTM)-US$66.33m
Revenue (TTM)US$714.00k

1,004x

P/S Ratio

-10.8x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
VBIV income statement (TTM)
RevenueUS$714.00k
Cost of RevenueUS$9.93m
Gross Profit-US$9.22m
ExpensesUS$57.11m
Earnings-US$66.33m

Last Reported Earnings

Sep 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.26
Gross Margin-1,291.04%
Net Profit Margin-9,290.20%
Debt/Equity Ratio17.4%

How did VBIV perform over the long term?

See historical performance and comparison

Valuation

Is VBI Vaccines undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: VBIV ($2.78) is trading below our estimate of fair value ($29.54)

Significantly Below Fair Value: VBIV is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: VBIV is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.

PE vs Market: VBIV is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate VBIV's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: VBIV is overvalued based on its PB Ratio (4.5x) compared to the US Biotechs industry average (2.9x).


Future Growth

How is VBI Vaccines forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

59.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: VBIV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: VBIV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: VBIV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: VBIV's revenue (78.1% per year) is forecast to grow faster than the US market (10.1% per year).

High Growth Revenue: VBIV's revenue (78.1% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if VBIV's Return on Equity is forecast to be high in 3 years time


Past Performance

How has VBI Vaccines performed over the past 5 years?

-13.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: VBIV is currently unprofitable.

Growing Profit Margin: VBIV is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: VBIV is unprofitable, and losses have increased over the past 5 years at a rate of 13.4% per year.

Accelerating Growth: Unable to compare VBIV's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VBIV is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (11%).


Return on Equity

High ROE: VBIV has a negative Return on Equity (-41.42%), as it is currently unprofitable.


Financial Health

How is VBI Vaccines's financial position?


Financial Position Analysis

Short Term Liabilities: VBIV's short term assets ($147.8M) exceed its short term liabilities ($32.9M).

Long Term Liabilities: VBIV's short term assets ($147.8M) exceed its long term liabilities ($31.1M).


Debt to Equity History and Analysis

Debt Level: VBIV has more cash than its total debt.

Reducing Debt: VBIV's debt to equity ratio has increased from 2.6% to 17.4% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: VBIV has sufficient cash runway for more than 3 years based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if VBIV has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Dividend

What is VBI Vaccines's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate VBIV's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate VBIV's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if VBIV's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if VBIV's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of VBIV's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.2yrs

Average management tenure


CEO

Jeff Baxter (60 yo)

5.5yrs

Tenure

US$2,246,985

Compensation

Mr. Jeffrey R. Baxter, FCMA, also known as Jeff, has been the Chief Executive Officer and President of VBI Vaccines Inc. since May 2016. Mr. Baxter has been the Chief Executive Officer and President of VBI...


CEO Compensation Analysis

Compensation vs Market: Jeff's total compensation ($USD2.25M) is about average for companies of similar size in the US market ($USD2.26M).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: VBIV's management team is considered experienced (4.2 years average tenure).


Board Members

Experienced Board: VBIV's board of directors are considered experienced (3.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 6.3%.


Top Shareholders

Company Information

VBI Vaccines Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: VBI Vaccines Inc.
  • Ticker: VBIV
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$715.307m
  • Shares outstanding: 257.30m
  • Website: https://www.vbivaccines.com

Number of Employees


Location

  • VBI Vaccines Inc.
  • 222 Third Street
  • Suite 2241
  • Cambridge
  • Massachusetts
  • 2142
  • United States

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/11/27 23:29
End of Day Share Price2021/11/26 00:00
Earnings2021/09/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.